Trial intelligence / Profile preview

Randomized, Double-Blind Trial of MP29-02 Nasal Spray vs Placebo, Azelastine, and Fluticasone in Seasonal Allergic Rhinitis

2011-001370-26Phase 3

Sponsor
Meda
Start
Mar 2011
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of azelastine + fluticasone in seasonal allergic rhinitis (SAR) (4 arms), sponsored by Meda. Primary endpoint: 12-hour reflective Total Nasal Symptom Score (TNSS).

02

Drugs

azelastine + fluticasone
03

Conditions

seasonal allergic rhinitis (SAR)

Beyond the preview

Go deeper on 2011-001370-26.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2011-001370-26.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call